Abstract
A growing number of European joint Health Technology Assessment (HTA) initiatives have emerged, driven by an increasing number of high-cost medicines. This research aims to provide an overview of the current cross-country HTA landscape and identify implications for orphan drugs (ODs) undergoing joint HTA.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
